Clinical trials: Psoriatic Arthritis
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
The primary objectives of this study are to assess whether there is transfer of Certolizumab Pegol (CZP) into breast milk of lactating mothers who are receiving an established dosing regimen of CZP by evaluating the concentration…
- Conditions
- Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- CRADLE (NCT02154425)
- Testing
- Breast milk sampling, Certolizumab Pegol
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 17 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Arthritis, Psoriatic
A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis
This study is open to adults with active psoriatic arthritis who have tender and swollen joints. The purpose of this study is to find out whether a medicine called BI 730357 helps to reduce symptoms and to prevent damage to…
- Trial name
- NCT04680676
- Testing
- BI 730357
- Sponsor
- Boehringer Ingelheim
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Ankylosing Spondylitis, Psoriatic Arthritis
Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Australia
The study is a cross sectional, epidemiology study of disease severity for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in four geographic regions in Australia (Illawarra, Sutherland, Hunter Urban and…
- Conditions
- Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis
- Trial name
- NCT00751387
- Where
- 4 sites in Australia
- Volunteers
- 559 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Crohn Disease, Ulcerative Colitis
SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
A prospective, longitudinal, multicentre, observational cohort follow-up study conducted in France.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- SAPHIR (NCT05598684)
- Where
- 96 sites in France, Guadeloupe and 1 more
- Volunteers
- 600 people
- Sponsor
- Fresenius Kabi, France
Moderate to Severe Psoriatic Arthritis
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
The purpose of this Phase 2a/b study is: 1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with psoriatic arthritis (PsA). 2.
- Trial name
- NCT07801495
- Testing
- DDY391
- Where
- 3 sites in United States
- Volunteers
- 220 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine
Safety and effectiveness, quality of life and work productivity of Humira in patients with psoriatic arthritis in clinical routine.
- Trial name
- ELAN (NCT01078610)
- Testing
- adalimumab (Humira)
- Sponsor
- Abbott
Psoriatic Arthritis
A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis
This is a Phase II, prospective, multicenter, randomized, double-blind, placebo-controlled, dose finding trial in parallel-groups with primary endpoint at Week 16 (visit V9) to investigate the efficacy, tolerability, safety…
- Trial name
- NCT04713072
- Testing
- ABY-035
- Where
- 32 sites in Austria, Belgium and 5 more
- Volunteers
- 129 people
- Sponsor
- ACELYRIN Inc.
Juvenile Psoriatic Arthritis
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
- Trial name
- NCT06100744
- Testing
- Adalimumab, Risankizumab
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.
- Trial name
- NCT00456092
- Testing
- Apremilast
- Where
- 38 sites in Belgium, Canada and 3 more
- Volunteers
- 204 people
- Sponsor
- Amgen
Psoriatic Arthritis
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.
- Trial name
- NCT02798211
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 58 sites in United States, Puerto Rico
- Volunteers
- 258 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.
- Trial name
- AMVISION-1 (NCT02029495)
- Testing
- 210 mg brodalumab, 140 mg brodalumab
- Where
- 152 sites in United States, Belgium and 15 more
- Volunteers
- 478 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriatic Arthritis
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
- Trial name
- NCT05511519
- Testing
- ATI-450
- Where
- 22 sites in United States, Poland
- Volunteers
- 47 people
- Sponsor
- Aclaris Therapeutics, Inc.
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNFα-IR)…
- Trial name
- BE COMPLETE (NCT03896581)
- Testing
- Bimekizumab
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 400 people
- Sponsor
- UCB Biopharma SRL
Spondylarthritis, Psoriatic Arthritis
A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
The objective of this study is to access retention rate, persistence and adherence in population of spondylarthritis (SpA) (ankylosing spondylitis (AS) and psoriatic arthritis (PsA)) participants treated with adalimumab in…
- Conditions
- Spondylarthritis, Psoriatic Arthritis, Ankylosing Spondylitis (AS)
- Trial name
- Adherence (NCT02988674)
- Where
- 14 sites in Russia
- Volunteers
- 139 people
- Sponsor
- AbbVie
Psoriasis, Psoriatic Arthritis
Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
This is a phase 4, multicenter, randomized, non-therapeutic interventional trial in subjects with psoriasis looking for the prevalence of psoriatic arthritis.
- Trial name
- PREPARE (NCT01147874)
- Testing
- lab draws and imaging
- Where
- 45 sites in United States, Belgium and 5 more
- Volunteers
- 1,013 people
- Sponsor
- Pfizer
Psoriatic Arthritis (PsA)
Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants
The purpose of this study is a long-term, observational study of Abatacept in patients with Psoriatic Arthritis, a chronic inflammatory disorder.
- Trial name
- ALTEA (NCT03419143)
- Where
- Germany
- Volunteers
- 190 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
This study was designed to leverage the sensitivity of ultrasonography available in clinical practice setting to better describe the time course of response to secukinumab (150 mg and 300 mg) on joint synovitis and enthesitis in…
- Trial name
- PDUS (NCT02662985)
- Testing
- AIN457 (secukinumab)
- Where
- 33 sites in United States, Argentina and 15 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA).
- Trial name
- VELOTA (NCT07321873)
- Testing
- JNJ-88545223
- Where
- 75 sites in United States, China and 6 more
- Volunteers
- 240 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis (PsA)
Psoriatic Arthritis Treat to Target vs. Usual Care
Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic Arthritis to a target (disease activity score <2.6), or as per their routine care.
- Trial name
- PRC-05-2011 (NCT01692912)
- Testing
- Intensive Care
- Where
- 4 sites in Canada
- Sponsor
- Pope Research Corporation